- Patent Title: Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
-
Application No.: US14440001Application Date: 2013-11-05
-
Publication No.: US09623015B2Publication Date: 2017-04-18
- Inventor: Stéphane Prost , Marek Kirszenbaum , Mikael Le Dantec , Philippe Rousselot , Philippe Leboulch
- Applicant: Commissariat à L'Energie Atomique et aux Energies Alternatives (CEA)
- Applicant Address: FR Paris
- Assignee: Commissariat à L'Energie Atomique et aux Energies Alternatives (CEA)
- Current Assignee: Commissariat à L'Energie Atomique et aux Energies Alternatives (CEA)
- Current Assignee Address: FR Paris
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Cynthia L. Kanik
- International Application: PCT/IB2013/002583 WO 20131105
- International Announcement: WO2014/068397 WO 20140508
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61K31/506 ; A61K45/06 ; A61K31/404 ; A61K31/426 ; A61K31/427 ; A61K31/496 ; A61K31/5025 ; A61K31/517 ; A61K31/519 ; A61K31/5377
Abstract:
Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARγ agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause relapse.
Public/Granted literature
Information query
IPC分类:
